US Biologic Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
US Biologic General Information
Description
Developer of an oral vaccine delivery platform designed to prevent infectious diseases. The company develops orally administered vaccines for humans and antimicrobial products to prevent zoonotic diseases, including Lyme disease, enabling healthcare providers and veterinarians to support disease prevention through convenient, cost-effective delivery methods.
Contact Information
Website
www.usbiologic.comCorporate Office
- 3 North Dunlap Street
- Memphis, TN 38103-2802
- United States
Corporate Office
- 3 North Dunlap Street
- Memphis, TN 38103-2802
- United States
US Biologic Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 01-Mar-2026 | Completed | Generating Revenue | |||
| 6. Grant | 15-Sep-2021 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 13-Oct-2017 | Completed | Generating Revenue | |||
| 4. Grant | 31-Dec-2016 | Completed | Generating Revenue | |||
| 3. Grant | 31-Dec-2015 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 03-Oct-2014 | $1.82M | $1.82M | Completed | Generating Revenue | |
| 1. Grant | 02-Dec-2013 | $2M | Completed | Generating Revenue |
US Biologic Comparisons
Industry
Financing
Details
US Biologic Competitors (1)
One of US Biologic’s competitors is Vaxart, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vaxart | Formerly VC-backed | South San Francisco, CA |
US Biologic Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
US Biologic Patents
US Biologic Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250276055-A1 | Visco-elastic solid formulation for oral delivery of a biologically active agent | Pending | 05-Nov-2022 | ||
| WO-2024097396-A1 | Visco-elastic solid formulation for oral delivery of a biologically active agent | Inactive | 05-Nov-2022 | ||
| CA-3205371-A1 | Method to reduce tick population with a universal tick antigen | Active | 15-Jan-2021 | ||
| CA-3205371-C | Method to reduce tick population with a universal tick antigen | Active | 15-Jan-2021 | ||
| US-11771746-B2 | Method to reduce tick population with a universal tick antigen | Active | 15-Jan-2021 | A61K39/0003 |
US Biologic Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
US Biologic Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biomedical Advanced Research and Development Authority | Government |
US Biologic FAQs
-
When was US Biologic founded?
US Biologic was founded in 2012.
-
Where is US Biologic headquartered?
US Biologic is headquartered in Memphis, TN.
-
What is the size of US Biologic?
US Biologic has 10 total employees.
-
What industry is US Biologic in?
US Biologic’s primary industry is Drug Delivery.
-
Is US Biologic a private or public company?
US Biologic is a Private company.
-
What is US Biologic’s current revenue?
The current revenue for US Biologic is .
-
How much funding has US Biologic raised over time?
US Biologic has raised $2.83M.
-
Who are US Biologic’s investors?
Biomedical Advanced Research and Development Authority has invested in US Biologic.
-
Who are US Biologic’s competitors?
Vaxart is a competitor of US Biologic.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
